SCHEMBL3709933

SCHEMBL3709933

CS(=O)(=O)Nc1cccc(-c2cnc3[nH]cc(C(=O)c4cc(C(N)=O)ccc4F)c3c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMKK2 Q96RR4 2/20 0.51
CYP2C9 P11712 3/20 0.50
CYP2C19 P33261 2/20 0.50
INSR P06213 2/20 0.48
MAPK8 P45983 2/20 0.48
CDC7 O00311 1/20 0.48
PLK4 O00444 1/20 0.48
CHEK1 O14757 1/20 0.48
AURKA O14965 1/20 0.48
MAPK13 O15264 1/20 0.48
PDPK1 O15530 1/20 0.48
DYRK3 O43781 1/20 0.48
ROCK2 O75116 1/20 0.48
RPS6KA5 O75582 1/20 0.48
PRKD3 O94806 1/20 0.48
PAK4 O96013 1/20 0.48
CHEK2 O96017 1/20 0.48
ABL1 P00519 1/20 0.48
EGFR P00533 1/20 0.48
NTRK1 P04629 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL299603 0.94 CYP2C9 (0.53) CAMKK2CYP2C9CYP2C19INSRMAPK8
SCHEMBL297360 0.91 CYP2C9 (0.56) CYP2C9CYP2C19ITKDYRK1ARIPK1
SCHEMBL298060 0.90 CYP2C9 (0.51) CYP2C9CYP2C19NTRK1ITKRIPK1
SCHEMBL415675 0.89 CYP2C9 (0.52) CYP2C9CYP2C19ITKDYRK1ARIPK1
SCHEMBL3706659 0.88 INSR (0.55) CAMKK2CYP2C9CYP2C19INSRMAPK8
SCHEMBL3702186 0.88 CAMKK2 (0.67) CAMKK2CYP2C9CYP2C19INSRMAPK8
SCHEMBL2886610 0.85 CYP2C19 (0.61) CYP2C9CYP2C19EGFRKDRNEK2
SCHEMBL299140 0.85 CYP2C19 (0.59) CYP2C9CYP2C19EGFRAXLKDR
SCHEMBL298879 0.84 CYP2C9 (0.49) CYP2C9CYP2C19DYRK1ARIPK1BRAF
SCHEMBL298449 0.84 CYP2C9 (0.53) CAMKK2CYP2C9CYP2C19PLK4DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2023-09-07 US disclosed
US-11337976-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2022-05-24 US disclosed
EP-2672967-B1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2018-10-17 EP disclosed
US-20170157120-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2017-06-08 US disclosed
US-9624213-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2017-04-18 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF CAMKK2 497/4885CYP2C9 2176/4885CYP2C19 2730/4885
US-11337976-B2 Compounds and methods for kinase modulation, and indications therefor MAP3K20, PRKACA, MAP3K13 CAMKK2 85/4885CYP2C9 4771/4885CYP2C19 4608/4885
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, PRKACA, MAP3K13 CAMKK2 85/4885CYP2C9 4771/4885CYP2C19 4608/4885
US-20170157120-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, PRKACA, MAP3K13 CAMKK2 85/4885CYP2C9 4771/4885CYP2C19 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.